These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease. Rinne UK. J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601 [Abstract] [Full Text] [Related]
4. (-)Deprenyl in the treatment of decompensated Parkinson's disease. Csanda E, Tárczy M, Takáts A. J Neural Transm Suppl; 1986; 22():247-52. PubMed ID: 3097259 [Abstract] [Full Text] [Related]
12. Practical therapeutics: advances in the management of Parkinson's disease. Adam AM. East Afr Med J; 1985 Feb 08; 62(2):143-6. PubMed ID: 3930202 [No Abstract] [Full Text] [Related]
15. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease. Presthus J, Hajba A. Acta Neurol Scand Suppl; 1983 Feb 08; 95():127-33. PubMed ID: 6428145 [Abstract] [Full Text] [Related]
16. MAO-B-Inhibitor selegiline (R-(-)-deprenyl). A new therapeutic concept in the treatment of Parkinson's disease. Proceedings of the international symposium. Berlin, January 23-25, 1987. J Neural Transm Suppl; 1987 Feb 08; 25():1-197. PubMed ID: 3123595 [No Abstract] [Full Text] [Related]
17. Deprenyl for the treatment of early Parkinson's disease. N Engl J Med; 1990 May 24; 322(21):1526-8. PubMed ID: 2110624 [No Abstract] [Full Text] [Related]